Kovacs, Zoltan
Vestergaard, Peter
W. Licht, Rasmus
P. V. Straszek, Sune
Hansen, Anne Sofie
H. Young, Allan
Duffy, Anne
Müller-Oerlinghausen, Bruno
Seemueller, Florian
Sani, Gabriele
Rubakowski, Janusz
Priller, Josef
Vedel Kessing, Lars
Tondo, Leonardo
Alda, Martin
Manchia, Mirko
Grof, Paul
Ritter, Phillip
Hajek, Tomas
Lewitzka, Ute
Bergink, Veerle
Bauer, Michael
Nielsen, René Ernst
Article History
Received: 18 September 2022
Accepted: 19 December 2022
First Online: 22 December 2022
Declarations
:
: Review article, i.e., not applicable.
: All authors have agreed to publish the final version of the article. The study does not include any patients, i.e., no patient consent is required.
: ZK has nothing to declare. PV has nothing to declare. RWL has within the last three years received speaker fees from Lundbeck, Janssen-Cilag and Teva, and fees from Janssen-Cilag for advisory board activity. SS has within the last three years received speakers fees from Lundbeck. ASH has nothing to declare. AY independent research is funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. AD has nothing to declare. BMO has nothing to declare. FS has received speaking fees for Janssen-Cilag, Aristo, Lundbeck, Servier and has acted as advisor to Janssen-Cilag and Lundbeck<b>.</b> GS has nothing to delclare<b>.</b> JR has nothing to declare<b>.</b> JP has nothing to declare<b>.</b> LVK has the last three years been a consultant for Lundbeck and Teva. LT has nothing to declare<b>.</b> MA has nothing to declare<b>.</b> MM has nothing to declare<b>.</b> PG has nothing to declare<b>.</b> PR has nothing to declare<b>.</b> TH has nothing to declare<b>.</b> UL has received research grants from BMBF, AFSP, BMG, ulinsky Foundation, Janssen-Cilag; honoraria for lecturing from Janssen-Cilag; honoraria for advisory board activity from Janssen-Cilag<b>.</b> VB has nothing to declare<b>.</b> MB has received research grants from Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), and European Commission. He has received honoraria for lecturing from Aristo, Janssen-Cilag, Janssen Pharmaceutica NV, and Servier Deutschland. He has served as a consultant for Biogen, GH Research, Janssen-Cilag, Livanova, Novartis, and Sunovion. REN has within the last three years been an investigator for Compass Pharmaceuticals, Janssen-Cilag, Sage and Boehringer-Ingelheim for clinical trials, has received speaking fees from Lundbeck, Teva Pharmaceuticals, Janssen-Cilag and Otsuka Pharmaceuticals, and has acted as advisor to Lundbeck and Janssen-Cilag.